Indication
Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
Loading your page…
Loading your page…
Carcinoma, Non-Small-Cell Lung
Marketing Authorisation Holder: Blueprint Medicines (Netherlands) B.V.
EMA Authorisation: 18/11/2021
INN: pralsetinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Gavreto: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.